Similarly, in colorectal cancer, YBX1 binds to the promoter and acts as a transcriptional activator of the EGFR gene, mediating resistance to anti-ERBB2 therapy and preventing apoptosis in ERBB2-overexpressing breast cancer cells through a complex RSK-dependent mechanism (9). This evidence concerns the gene ERBB2 and breast carcinoma.